Skip to main content

Advertisement

SpringerLink
Log in

Extraintestinal manifestations of inflammatory bowel disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The idiopathic inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, may be complicated by extraintestinal manifestations (EIMs) in up to 40% of patients. Reports suggest that almost every organ system may be affected. The EIMs are a significant cause of morbidity and may be particularly distressing for the patient. Recent attempts have been made to define the phenotype of IBD in patients of different ethnicities. These studies have highlighted potential racial variations in the prevalence of specific EIMs, findings that are perhaps not surprising given the influence of genetic factors in their pathogenesis. Certain EIMs are related to the activity of the bowel disease, and their management often involves careful monitoring while the IBD is brought under control. Other EIMs, however, typically run a course independent of the IBD activity, and specific, targeted treatments may be required, even including biologic agents such as infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004, 10:207–214.

    Article  PubMed  Google Scholar 

  2. Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976, 55:401–412.

    CAS  Google Scholar 

  3. Bernstein CN, Wajda A, Blanchard JF: The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129:827–836.

    Article  PubMed  Google Scholar 

  4. Cappell MS, Turkieh A: Chronic pericarditis and pericardial tamponade associated with ulcerative colitis. Dig Dis Sci 2008, 53:149–154.

    Article  PubMed  Google Scholar 

  5. Watanabe T: Parotitis and acute pancreatitis in a patient with ulcerative colitis. Eur J Pediatr 2008, 167:945.

    Article  PubMed  Google Scholar 

  6. Mahid SS, Mulhall AM, Gholson RD, et al.: Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008, 14:960–967.

    Article  PubMed  Google Scholar 

  7. Nguyen GC, Torres EA, Regueiro M, et al.: Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006, 101:1012–1023.

    Article  PubMed  Google Scholar 

  8. Basu D, Lopez I, Kulkarni A, Sellin JH: Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005, 100:2254–2261.

    Article  PubMed  Google Scholar 

  9. Rodriguez VE, Costas PJ, Vazquez M, et al.: Prevalence of spondyloarthropathy in Puerto Rican patients with inflammatory bowel disease. Ethn Dis 2008, 18(Suppl 2):225–229.

    Google Scholar 

  10. Lanna CC, Ferrari M, Rocha SL, et al.: A cross-sectional study of 130 Brazilian patients with Crohn’s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008, 27:503–509.

    Article  PubMed  Google Scholar 

  11. Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274–278.

    Article  PubMed  CAS  Google Scholar 

  12. Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714–718.

    Article  PubMed  Google Scholar 

  13. Roussomoustakaki M, Satsangi J, Welsh K, et al.: Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997, 112:1845–1853.

    Article  PubMed  CAS  Google Scholar 

  14. Williams HRT, Sato H, Welsh KI, et al.: Clinical and genetic associations of pyoderma gangrenosum in patients with inflammatory bowel disease: evidence for a shared predisposition to extraintestinal manifestations [abstract]. Gut 2007, 56(Suppl III):A21. Presented at United European Gastroenterology Week. Paris; October 2007.

    Google Scholar 

  15. Peeters H, Vander Cruyssen B, Laukens D, et al.: Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 2004, 63:1131–1134.

    Article  PubMed  CAS  Google Scholar 

  16. Peeters H, Vander Cruyssen B, Mielants H, et al.: Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 2008, 23:132–137.

    PubMed  Google Scholar 

  17. Mielants H, Veys EM, De Vos M, et al.: The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995, 22:2266–2272.

    PubMed  CAS  Google Scholar 

  18. Elewaut D, De Keyser F, Van Den Bosch F, et al.: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998, 25:1932–1937.

    PubMed  CAS  Google Scholar 

  19. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387–391.

    Article  PubMed  CAS  Google Scholar 

  20. Travis SP, Stange EF, Lémann M, et al.; European Crohn’s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006, 55(Suppl 1):i16–i35.

    Article  PubMed  Google Scholar 

  21. Fornaciari G, Salvarini C, Beltrami M, et al.: Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399–403.

    PubMed  CAS  Google Scholar 

  22. Steer S, Jones H, Hibbert J, Kondeatis, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003, 30:518–522.

    PubMed  Google Scholar 

  23. Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al.: Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978, 37:33–35.

    Article  PubMed  CAS  Google Scholar 

  24. Brown MA, Pile KD, Kennedy LG, et al.: HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996, 55:268–270.

    Article  PubMed  CAS  Google Scholar 

  25. Orchard T, Holt H, Bradley L, et al.: Prevalence of sacroiliitis in Crohn’s disease, and its correlation with clinical, radiologic and genotypic parameters [abstract]. Gastroenterology 2002, 122(Suppl 4):W1298.

    Google Scholar 

  26. Thjodleifsson B, Geirsson AJ, Björnsson S, Bjarnason I: A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007, 56:2633–2639.

    Article  PubMed  Google Scholar 

  27. Rahman P, Inman RD, Gladman DD, et al.: Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008, 58:1020–1025.

    Article  PubMed  CAS  Google Scholar 

  28. Duerr RH, Taylor KD, Brant SR, et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461–1463.

    Article  PubMed  CAS  Google Scholar 

  29. Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273–290.

    Article  PubMed  CAS  Google Scholar 

  30. Felder JB, Korelitz BI, Rajapakse R, et al.: Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949–1954.

    Article  PubMed  CAS  Google Scholar 

  31. Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619–622.

    PubMed  CAS  Google Scholar 

  32. Takeuchi K, Smale S, Premshand P, et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196–202.

    Article  PubMed  CAS  Google Scholar 

  33. Bonner GF, Fakhri A, Vennamaneni SR: A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751–757.

    Article  PubMed  Google Scholar 

  34. Dougados M, Dijkmans B, Khan M, et al.: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40–50.

    Google Scholar 

  35. Chen J, Liu C, Lin J: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006, CD004524.

  36. Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325–2329.

    Article  PubMed  CAS  Google Scholar 

  37. Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618–627.

    Article  PubMed  CAS  Google Scholar 

  38. Taggart A, Gardiner P, McEvoy F, et al.: Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996, 39:1400–1405.

    Article  PubMed  CAS  Google Scholar 

  39. van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA: Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003, 30:1558–1560.

    PubMed  Google Scholar 

  40. Thomson GT, Thomson BR, Thomson KS, Ducharme JS: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000, 27:714–718.

    PubMed  CAS  Google Scholar 

  41. Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000, 27:723–726.

    PubMed  CAS  Google Scholar 

  42. Karimi O, Peña AS: Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev Esp Enferm Dig 2005, 97:570–574.

    Article  PubMed  CAS  Google Scholar 

  43. Levine JB, Lukawski-Trubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Amer 1995, 24:633–646.

    CAS  Google Scholar 

  44. Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664–1669.

    Article  PubMed  CAS  Google Scholar 

  45. Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639–647.

    Article  PubMed  CAS  Google Scholar 

  46. Timani S, Mutasim DF: Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008, 26:265–273.

    Article  PubMed  Google Scholar 

  47. Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996, 23:29–34.

    Article  PubMed  CAS  Google Scholar 

  48. Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005, 81:580–585.

    Article  PubMed  CAS  Google Scholar 

  49. Tavarela Veloso F: Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):50–53.

    Article  PubMed  Google Scholar 

  50. Callen JP: Pyoderma gangrenosum. Lancet 1998, 351:581–585.

    Article  PubMed  CAS  Google Scholar 

  51. Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333:181–184.

    Article  PubMed  Google Scholar 

  52. Chow RK, Ho VC: Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996, 34:1047–1060.

    Article  PubMed  CAS  Google Scholar 

  53. Brooklyn TN, Dunnill MG, Shetty A, et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505–509.

    Article  PubMed  CAS  Google Scholar 

  54. Girardin M, Waschke KA, Seidman EG: A case of acute loss of vision as the presenting symptom of Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:695–698.

    Article  PubMed  Google Scholar 

  55. Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135–139.

    Article  PubMed  Google Scholar 

  56. Loftus EV: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2004, 6:506–513.

    Article  PubMed  Google Scholar 

  57. Hale S, Lightman S: Anti-TNF therapies in the treatment of acute and chronic uveitis. Cytokine 2006, 33:231–237.

    Article  PubMed  CAS  Google Scholar 

  58. Moff SL, Kamel IR, Eustace J, et al.: Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006, 64:219–223.

    Article  PubMed  Google Scholar 

  59. MacFaul GR, Chapman RW: Sclerosing cholangitis. Curr Opinion Gastroenterol 2004, 20:275–280.

    Article  Google Scholar 

  60. Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39–45.

    Article  PubMed  Google Scholar 

  61. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691–695.

    Article  PubMed  CAS  Google Scholar 

  62. Mitchell SA, Bansi DA, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900–907.

    Article  PubMed  CAS  Google Scholar 

  63. Olsson R, Boberg KM, de Muckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464–1472.

    Article  PubMed  CAS  Google Scholar 

  64. Cullen SN, Chapman RW: Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933–948.

    Article  PubMed  CAS  Google Scholar 

  65. Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815–822.

    Article  PubMed  CAS  Google Scholar 

  66. Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002, 51:v10–v12.

    Article  PubMed  Google Scholar 

  67. Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783–788.

    Article  PubMed  CAS  Google Scholar 

  68. Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889–893.

    Article  PubMed  CAS  Google Scholar 

  69. Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK: Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007, 13:6156–6165.

    Article  PubMed  Google Scholar 

  70. Lamb EJ, Wong T, Smith DJ, et al.: Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1895–1902.

    Article  PubMed  CAS  Google Scholar 

  71. Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251–255.

    Article  PubMed  CAS  Google Scholar 

  72. Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1–10.

    Article  PubMed  Google Scholar 

  73. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795–841

    Article  PubMed  Google Scholar 

  74. American Gastroenterological Association: Medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791–794.

    Article  Google Scholar 

  75. Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004, 15:511–519.

    Article  PubMed  CAS  Google Scholar 

  76. Henderson S, Hoffman N, Prince RA: Double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119–123.

    Article  PubMed  CAS  Google Scholar 

  77. Raj AA, Birring SS, Green R, et al.: Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008, 102:780–785.

    Article  PubMed  CAS  Google Scholar 

  78. Izzedine H, Simon J, Piette AM, et al.: Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology 2002, 123:1436–1440.

    Article  PubMed  Google Scholar 

  79. Marcus SB, Brown JB, Melin-Aldana H, Strople JA: Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008, 46:338–341.

    PubMed  Google Scholar 

  80. Archimandritis AJ, Weetch MS: Kidney granuloma in Crohn’s disease. BMJ 1993, 307:540–541.

    Article  PubMed  CAS  Google Scholar 

  81. Baumer P, Brocard JF, Kohn W, et al.: Severe chronic interstitial nephritis associated with Crohn’s disease, but not with mesalazine? Gastroenterol Clin Biol 1999, 23:1400–1402.

    PubMed  CAS  Google Scholar 

  82. Unal A, Sipahioglu MH, Akgun H, et al.: Crohn’s disease complicated by granulomatous interstitial nephritis, choroidal neovascularization, and central retinal vein occlusion. Intern Med 2008, 47:103–107.

    Article  PubMed  Google Scholar 

  83. Scheid R, Teich N: Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007, 14:483–493.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial College London, St. Mary’s Hospital Campus, GI Unit, 3rd Floor Clarence Wing, St. Mary’s Hospital, Praed Street, London, W2 1NY, UK

    Timothy R. Orchard

Authors
  1. Horace Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy R. Orchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy R. Orchard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, H., Walker, D. & Orchard, T.R. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 10, 597–605 (2008). https://doi.org/10.1007/s11894-008-0108-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-008-0108-6

Keywords

Search

Navigation